PF-04958242

Generic Name
PF-04958242
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H20N2O4S2
CAS Number
1258963-59-5
Unique Ingredient Identifier
9G1A824CC2
Background

PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

First Posted Date
2016-08-04
Last Posted Date
2020-01-09
Lead Sponsor
Biogen
Target Recruit Count
35
Registration Number
NCT02855411
Locations
🇺🇸

Collaborative Neuroscience Network, LLC, Torrance, California, United States

🇺🇸

Atlanta Center For Medical Research, Atlanta, Georgia, United States

🇺🇸

Pillar Clinical Research, LLC, Dallas, Texas, United States

and more 12 locations

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: PF-04958242
Drug: Itraconazole
First Posted Date
2015-01-19
Last Posted Date
2020-01-09
Lead Sponsor
Biogen
Target Recruit Count
13
Registration Number
NCT02341482
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: PF-04958242
Drug: Placebo
First Posted Date
2015-01-07
Last Posted Date
2021-10-25
Lead Sponsor
Biogen
Target Recruit Count
39
Registration Number
NCT02332798
Locations
🇺🇸

Collaborative Neuroscience Network, LLC., Long Beach, California, United States

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: PF-04958242
Drug: Placebo
First Posted Date
2014-08-29
Last Posted Date
2020-01-07
Lead Sponsor
Biogen
Target Recruit Count
12
Registration Number
NCT02228395
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
Drug: PF-04958242
Drug: Ketamine
First Posted Date
2012-12-13
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
29
Registration Number
NCT01749098
Locations
🇺🇸

Pfizer Investigational Site, West Haven, Connecticut, United States

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: PF-04958242
Drug: Placebo
First Posted Date
2012-01-26
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
30
Registration Number
NCT01518894
Locations
🇺🇸

Pfizer Investigational Site, Long Beach, California, United States

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Phase 1
Completed
Conditions
Hearing Loss, Sensorineural
Interventions
Drug: PF-04958242
Drug: Placebo
First Posted Date
2012-01-26
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
44
Registration Number
NCT01518920
Locations
🇺🇸

Pfizer Investigational Site, Dallas, Texas, United States

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: PF-04958242
Drug: Placebo
First Posted Date
2012-01-18
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
39
Registration Number
NCT01511510
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Placebo
Drug: PF-04958242
First Posted Date
2011-06-03
Last Posted Date
2019-12-24
Lead Sponsor
Biogen
Target Recruit Count
112
Registration Number
NCT01365338
Locations
🇺🇸

Research Site, New Haven, Connecticut, United States

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Phase 1
Terminated
Conditions
Healthy Volunteers
Interventions
Drug: PF-04958242
Drug: Placebo
First Posted Date
2010-11-10
Last Posted Date
2019-12-24
Lead Sponsor
Biogen
Target Recruit Count
20
Registration Number
NCT01238679
Locations
🇸🇬

Research Site, Singapore, Singapore

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy